Examining the Long-term Clinical Evidence of Therapies for Inflammatory Bowel Disease in Bio-naïve Patients : Episode 14

Opinion

Video

July 12, 2023

The Role of Ustekinumab in UC

Author(s):

David P. Hudesman, MD,Maia Kayal, MD

Millie Long, David Hudesman, MD, Maia Kayal, MD, and Miguel Regueiro, MD, discuss treatment strategies for ulcerative colitis (UC) utilizing ustekinumab.

EP: 1.Overview of IBD

EP: 2.Treatment Factors of IBD

EP: 3.Managing Care for IBD Patients Not Responding to Treatment

EP: 4.Selecting First-Line Treatments for CD

EP: 5.The Role of Vedolizumab and Risankizumab in CD

EP: 6.Efficacy and Safety of Ustekinumab for CD

EP: 7.Selecting Therapies for CD in Pregnancy

EP: 8.Selecting Treatments in Patients With EIM

EP: 9.Second-Line Therapies for CD

EP: 10.Optimizing Therapies for CD

EP: 11.Major Takeaways for Treating CD

EP: 12.Treatment Approaches for Patients With UC

EP: 13.The Role of Ozanimod in UC

Now Viewing

The Role of Ustekinumab in UC

EP: 1.Overview of IBD

EP: 2.Treatment Factors of IBD

EP: 3.Managing Care for IBD Patients Not Responding to Treatment

EP: 4.Selecting First-Line Treatments for CD

EP: 5.The Role of Vedolizumab and Risankizumab in CD

EP: 6.Efficacy and Safety of Ustekinumab for CD

EP: 7.Selecting Therapies for CD in Pregnancy

EP: 8.Selecting Treatments in Patients With EIM

EP: 9.Second-Line Therapies for CD

EP: 10.Optimizing Therapies for CD

EP: 11.Major Takeaways for Treating CD

EP: 12.Treatment Approaches for Patients With UC

EP: 13.The Role of Ozanimod in UC

EP: 14.The Role of Ustekinumab in UC

EP: 15.Utilizing JAK Inhibitors in Patients With UC

EP: 16.Treatment Sequencing for UC

EP: 17.Biosimilar Treatment Options for Patients With UC

EP: 18.Key Takeaways and Prospective Treatment Advances